17 Jul 2023 argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy Member news
10 Jul 2023 Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure Member news
03 Jul 2023 AMA issues CPT III code for icometrix’ AI-related brain MRI quantification software Member news
30 Jun 2023 argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China Member news
21 Jun 2023 argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis Member news
12 Jun 2023 Oxurion finalizes enrollment in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
